Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/182662 |
Resumo: | Doxorubicin (Dox) clinical use is limited by dose-related cardiomyopathy, becoming more prevalent with increasing cumulative doses. Previously, we developed Dox-loaded lipid-core nanocapsules (Dox-LNC) and, in this study, we hypothesized that self-assembling and interfacial reactions could be used to obtain arginylglycylaspartic acid (RGD)-surface-functionalized-Dox-LNC, which could target tumoral cells overexpressing v 3 integrin. Human breast adenocarcinoma cell line (MCF-7) and human glioblastoma astrocytoma (U87MG) expressing different levels of v 3 integrin were studied. RGD-functionalized Dox-LNC were prepared with Dox at 100 and 500 mg mL1 (RGD-MCMN (Dox100) and RGD-MCMN (Dox500)). Blank formulation (RGD-MCMN) had z-average diameter of 162 6 nm, polydispersity index of 0.11 0.04, zeta potential of +13.2 1.9 mV and (6.2 1.1) 1011 particles mL1, while RGD-MCMN (Dox100) and RGD-MCMN (Dox500) showed respectively 146 20 and 215 25 nm, 0.10 0.01 and 0.09 0.03, +13.8 2.3 and +16.4 1.5 mV and (6.9 0.6) 1011 and (6.1 1.0) 1011 particles mL1. RGD complexation was 7.73 104 molecules per nanocapsule and Dox loading were 1.51 104 and 7.64 104 molecules per nanocapsule, respectively. RGD-functionalized nanocapsules had an improved uptake capacity by U87MG cells. Pareto chart showed that the cell viability was mainly affected by the Dox concentration and the period of treatment in both MCF-7 and U87MG. The influence of RGD-functionalization on cell viability was a determinant factor exclusively to U87MG. |
id |
UFRGS-2_c123524838131ff2f666fada9f2efea5 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/182662 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Antonow, Michelli BarcelosFranco, CamilaPrado, Willian AndradeBeckenkamp, AlineSilveira, Gustavo PozzaBuffon, AndreiaGuterres, Silvia StanisçuaskiPohlmann, Adriana Raffin2018-09-26T02:33:35Z20182079-4991http://hdl.handle.net/10183/182662001076172Doxorubicin (Dox) clinical use is limited by dose-related cardiomyopathy, becoming more prevalent with increasing cumulative doses. Previously, we developed Dox-loaded lipid-core nanocapsules (Dox-LNC) and, in this study, we hypothesized that self-assembling and interfacial reactions could be used to obtain arginylglycylaspartic acid (RGD)-surface-functionalized-Dox-LNC, which could target tumoral cells overexpressing v 3 integrin. Human breast adenocarcinoma cell line (MCF-7) and human glioblastoma astrocytoma (U87MG) expressing different levels of v 3 integrin were studied. RGD-functionalized Dox-LNC were prepared with Dox at 100 and 500 mg mL1 (RGD-MCMN (Dox100) and RGD-MCMN (Dox500)). Blank formulation (RGD-MCMN) had z-average diameter of 162 6 nm, polydispersity index of 0.11 0.04, zeta potential of +13.2 1.9 mV and (6.2 1.1) 1011 particles mL1, while RGD-MCMN (Dox100) and RGD-MCMN (Dox500) showed respectively 146 20 and 215 25 nm, 0.10 0.01 and 0.09 0.03, +13.8 2.3 and +16.4 1.5 mV and (6.9 0.6) 1011 and (6.1 1.0) 1011 particles mL1. RGD complexation was 7.73 104 molecules per nanocapsule and Dox loading were 1.51 104 and 7.64 104 molecules per nanocapsule, respectively. RGD-functionalized nanocapsules had an improved uptake capacity by U87MG cells. Pareto chart showed that the cell viability was mainly affected by the Dox concentration and the period of treatment in both MCF-7 and U87MG. The influence of RGD-functionalization on cell viability was a determinant factor exclusively to U87MG.application/pdfengNanomaterials. Suíça. Vol. 8, no. 1 (2018), p. 1-18Nanocápsulas de núcleo lipídicoCâncerDoxorrubicinaLipid-core nanocapsulesCancerRGDDoxorubicinActive drug targetingSurface-functionalizationArginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cellsEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL001076172.pdfTexto completo (inglês)application/pdf3057755http://www.lume.ufrgs.br/bitstream/10183/182662/1/001076172.pdf7567c3765ac47801fafec85960db69e1MD51TEXT001076172.pdf.txt001076172.pdf.txtExtracted Texttext/plain63642http://www.lume.ufrgs.br/bitstream/10183/182662/2/001076172.pdf.txt73ef65602bf2ad488521b51143392696MD52THUMBNAIL001076172.pdf.jpg001076172.pdf.jpgGenerated Thumbnailimage/jpeg1833http://www.lume.ufrgs.br/bitstream/10183/182662/3/001076172.pdf.jpg5e2f0ea000dc144a0c9ca31062741f78MD5310183/1826622018-10-05 07:58:38.833oai:www.lume.ufrgs.br:10183/182662Repositório InstitucionalPUBhttps://lume.ufrgs.br/oai/requestlume@ufrgs.bropendoar:2018-10-05T10:58:38Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells |
title |
Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells |
spellingShingle |
Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells Antonow, Michelli Barcelos Nanocápsulas de núcleo lipídico Câncer Doxorrubicina Lipid-core nanocapsules Cancer RGD Doxorubicin Active drug targeting Surface-functionalization |
title_short |
Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells |
title_full |
Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells |
title_fullStr |
Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells |
title_full_unstemmed |
Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells |
title_sort |
Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells |
author |
Antonow, Michelli Barcelos |
author_facet |
Antonow, Michelli Barcelos Franco, Camila Prado, Willian Andrade Beckenkamp, Aline Silveira, Gustavo Pozza Buffon, Andreia Guterres, Silvia Stanisçuaski Pohlmann, Adriana Raffin |
author_role |
author |
author2 |
Franco, Camila Prado, Willian Andrade Beckenkamp, Aline Silveira, Gustavo Pozza Buffon, Andreia Guterres, Silvia Stanisçuaski Pohlmann, Adriana Raffin |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Antonow, Michelli Barcelos Franco, Camila Prado, Willian Andrade Beckenkamp, Aline Silveira, Gustavo Pozza Buffon, Andreia Guterres, Silvia Stanisçuaski Pohlmann, Adriana Raffin |
dc.subject.por.fl_str_mv |
Nanocápsulas de núcleo lipídico Câncer Doxorrubicina |
topic |
Nanocápsulas de núcleo lipídico Câncer Doxorrubicina Lipid-core nanocapsules Cancer RGD Doxorubicin Active drug targeting Surface-functionalization |
dc.subject.eng.fl_str_mv |
Lipid-core nanocapsules Cancer RGD Doxorubicin Active drug targeting Surface-functionalization |
description |
Doxorubicin (Dox) clinical use is limited by dose-related cardiomyopathy, becoming more prevalent with increasing cumulative doses. Previously, we developed Dox-loaded lipid-core nanocapsules (Dox-LNC) and, in this study, we hypothesized that self-assembling and interfacial reactions could be used to obtain arginylglycylaspartic acid (RGD)-surface-functionalized-Dox-LNC, which could target tumoral cells overexpressing v 3 integrin. Human breast adenocarcinoma cell line (MCF-7) and human glioblastoma astrocytoma (U87MG) expressing different levels of v 3 integrin were studied. RGD-functionalized Dox-LNC were prepared with Dox at 100 and 500 mg mL1 (RGD-MCMN (Dox100) and RGD-MCMN (Dox500)). Blank formulation (RGD-MCMN) had z-average diameter of 162 6 nm, polydispersity index of 0.11 0.04, zeta potential of +13.2 1.9 mV and (6.2 1.1) 1011 particles mL1, while RGD-MCMN (Dox100) and RGD-MCMN (Dox500) showed respectively 146 20 and 215 25 nm, 0.10 0.01 and 0.09 0.03, +13.8 2.3 and +16.4 1.5 mV and (6.9 0.6) 1011 and (6.1 1.0) 1011 particles mL1. RGD complexation was 7.73 104 molecules per nanocapsule and Dox loading were 1.51 104 and 7.64 104 molecules per nanocapsule, respectively. RGD-functionalized nanocapsules had an improved uptake capacity by U87MG cells. Pareto chart showed that the cell viability was mainly affected by the Dox concentration and the period of treatment in both MCF-7 and U87MG. The influence of RGD-functionalization on cell viability was a determinant factor exclusively to U87MG. |
publishDate |
2018 |
dc.date.accessioned.fl_str_mv |
2018-09-26T02:33:35Z |
dc.date.issued.fl_str_mv |
2018 |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/182662 |
dc.identifier.issn.pt_BR.fl_str_mv |
2079-4991 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001076172 |
identifier_str_mv |
2079-4991 001076172 |
url |
http://hdl.handle.net/10183/182662 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Nanomaterials. Suíça. Vol. 8, no. 1 (2018), p. 1-18 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/182662/1/001076172.pdf http://www.lume.ufrgs.br/bitstream/10183/182662/2/001076172.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/182662/3/001076172.pdf.jpg |
bitstream.checksum.fl_str_mv |
7567c3765ac47801fafec85960db69e1 73ef65602bf2ad488521b51143392696 5e2f0ea000dc144a0c9ca31062741f78 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
lume@ufrgs.br |
_version_ |
1817725032176025600 |